JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol.37, no.4, pp.236-240, 2021 (SCI-Expanded)
Purpose: Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives.